GlaxoSmithKline Announces Agreement With the Government of Burundi to Increase Access to HIV/AIDS Medicines

Apr 29, 2001, 01:00 ET from GlaxoSmithKline plc

    LONDON, April 29 /PRNewswire/ -- GlaxoSmithKline (NYSE:   GSK) today
 welcomed the announcement by the Government of Burundi of the agreement to
 increase access to HIV/AIDS medicines in partnership with the pharmaceutical
 industry and five UN agencies.  Burundi is the seventh African country to sign
 an agreement of this kind under the UNAIDS Accelerating Access Initiative
 (AAI), following an announcement by Mali earlier this month. This announcement
 coincides with National AIDS Day in Burundi.
     In order to ensure the long term sustainable supply of quality AIDS
 medicines, the National AIDS Programme, headed by Dr Joseph Wakana, on behalf
 of the government, has secured an agreement with four of the five research-
 based pharmaceutical companies participating in the UNAIDS initiative:  GSK,
 Merck, Boehringer Ingelheim and Bristol-Myers Squibb. As a result of this
 agreement, Burundi will receive anti-retro viral medicines at heavily
 discounted prices.
     As part of this agreement, GSK is offering a preferential price of US$2
 per day for its product Combivir which represents a 90% reduction on the world
 average price.
     The agreement will allow the Burundi Government to increase the number of
 patients fourfold in the next 12 months, through offering a range of
 therapeutic options to patients and physicians at preferential prices.
     Andrew Bulloch, Head of Eastern Africa Pharmaceuticals for GSK, commented:
     "We are delighted at the announcement of Burundi's participation in the
 Accelerating Access Initiative.  We look forward to working in partnership
 with the Government of Burundi to fulfill our commitment to increasing access
 to HIV/AIDS medicines in the developing world.
     "Through its undertakings to improve its healthcare infrastructure and
 treatment facilities, the Government of Burundi has shown that addressing the
 AIDS situation is a priority.  In the struggle against HIV/AIDS, political
 will is a necessary requirement if the Accelerating Access Initiative is to
 have any real effect. The Government of Burundi further demonstrated its
 commitment to addressing the country's AIDS problem by eliminating import
 taxes on all drugs including anti-retro virals.
     "We hope that other countries in Africa, and the rest of the developing
 world, will approach the challenge of AIDS with the same determination as
 those countries currently participating in the initiative".
     This announcement brings the number of African countries participating in
 the Accelerating Access Initiative to seven: Uganda, Senegal, Cote d'Ivoire,
 Rwanda, Cameroon, Mali and now Burundi.  The Initiative is supported by WHO,
 UNICEF, the World Bank, the UNFPA and UNAIDS.
 
     Notes:
 
     1) Since 1997, GSK has been offering discounts on its HIV/AIDS medicines
        which now total up to 90% off prices in the developed world.
 
     2) GSK is a founding partner of the UNAIDS Accelerating Access Initiative
        (AAI).  AAI is a public-private partnership involving five United
        Nations Agencies (UNAIDS, WHO, the World Bank, the United Nations
        Children's Fund (UNICEF), and the United Nations Population Fund
        (UNFPA)) as well as five R&D based multi-national pharmaceutical
        companies (Boehringer Ingelheim, Bristol-Myers Squibb, GSK, Merck &
        Co., Inc., and F. Hoffmann - La Roche) working alongside national
        governments.
 
     3) As part of the commitment the company offers preferential prices on
       anti-retro viral medicines to UN-supported and nationally-led HIV
       prevention and care initiatives for use in developing countries. These
       simultaneously address the healthcare infrastructure and drug
       distribution issues which are necessary to ensure access to safe and
       effective treatment.
 
     4) GSK's Chief Executive Officer, JP Garnier, in February announced an
        extension of the Accelerating Access Initiative to enable employers and
        NGOs, working on the ground in developing countries, to purchase the
        necessary medicines at preferential prices.
 
     5) In addition to HIV/AIDS, GSK is making significant contributions to
        combat other health problems in the developing world, including
        malaria, tuberculosis, Lymphatic Filariasis, and childhood
        immunization.
 
     Lymphatic Filariasis (LF): The company is working to help eradicate
 Lymphatic Filariasis, one of the world's major tropical diseases that causes
 life-long disability and disfigurement, through grants for public-private
 partnerships and donations of albendazole.  GSK has committed to donating
 albendazole for 15-20 years until LF is eliminated, making this the largest
 drug donation programme in history.
 
     Vaccines:  In addition to donating vaccines to a number of countries for
 specific programmes, the company continues to research better vaccines against
 diseases that affect developing countries, including malaria, tuberculosis and
 HIV/AIDS.
 
     Action TB:  Glaxo Wellcome established the Action TB fund in 1993.  This
 international, co-ordinated research programme aims to find new targets for
 anti-TB therapies, and identify novel vaccine candidates and surrogate markers
 for use in clinical trials.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X25437144
 
 

SOURCE GlaxoSmithKline plc
    LONDON, April 29 /PRNewswire/ -- GlaxoSmithKline (NYSE:   GSK) today
 welcomed the announcement by the Government of Burundi of the agreement to
 increase access to HIV/AIDS medicines in partnership with the pharmaceutical
 industry and five UN agencies.  Burundi is the seventh African country to sign
 an agreement of this kind under the UNAIDS Accelerating Access Initiative
 (AAI), following an announcement by Mali earlier this month. This announcement
 coincides with National AIDS Day in Burundi.
     In order to ensure the long term sustainable supply of quality AIDS
 medicines, the National AIDS Programme, headed by Dr Joseph Wakana, on behalf
 of the government, has secured an agreement with four of the five research-
 based pharmaceutical companies participating in the UNAIDS initiative:  GSK,
 Merck, Boehringer Ingelheim and Bristol-Myers Squibb. As a result of this
 agreement, Burundi will receive anti-retro viral medicines at heavily
 discounted prices.
     As part of this agreement, GSK is offering a preferential price of US$2
 per day for its product Combivir which represents a 90% reduction on the world
 average price.
     The agreement will allow the Burundi Government to increase the number of
 patients fourfold in the next 12 months, through offering a range of
 therapeutic options to patients and physicians at preferential prices.
     Andrew Bulloch, Head of Eastern Africa Pharmaceuticals for GSK, commented:
     "We are delighted at the announcement of Burundi's participation in the
 Accelerating Access Initiative.  We look forward to working in partnership
 with the Government of Burundi to fulfill our commitment to increasing access
 to HIV/AIDS medicines in the developing world.
     "Through its undertakings to improve its healthcare infrastructure and
 treatment facilities, the Government of Burundi has shown that addressing the
 AIDS situation is a priority.  In the struggle against HIV/AIDS, political
 will is a necessary requirement if the Accelerating Access Initiative is to
 have any real effect. The Government of Burundi further demonstrated its
 commitment to addressing the country's AIDS problem by eliminating import
 taxes on all drugs including anti-retro virals.
     "We hope that other countries in Africa, and the rest of the developing
 world, will approach the challenge of AIDS with the same determination as
 those countries currently participating in the initiative".
     This announcement brings the number of African countries participating in
 the Accelerating Access Initiative to seven: Uganda, Senegal, Cote d'Ivoire,
 Rwanda, Cameroon, Mali and now Burundi.  The Initiative is supported by WHO,
 UNICEF, the World Bank, the UNFPA and UNAIDS.
 
     Notes:
 
     1) Since 1997, GSK has been offering discounts on its HIV/AIDS medicines
        which now total up to 90% off prices in the developed world.
 
     2) GSK is a founding partner of the UNAIDS Accelerating Access Initiative
        (AAI).  AAI is a public-private partnership involving five United
        Nations Agencies (UNAIDS, WHO, the World Bank, the United Nations
        Children's Fund (UNICEF), and the United Nations Population Fund
        (UNFPA)) as well as five R&D based multi-national pharmaceutical
        companies (Boehringer Ingelheim, Bristol-Myers Squibb, GSK, Merck &
        Co., Inc., and F. Hoffmann - La Roche) working alongside national
        governments.
 
     3) As part of the commitment the company offers preferential prices on
       anti-retro viral medicines to UN-supported and nationally-led HIV
       prevention and care initiatives for use in developing countries. These
       simultaneously address the healthcare infrastructure and drug
       distribution issues which are necessary to ensure access to safe and
       effective treatment.
 
     4) GSK's Chief Executive Officer, JP Garnier, in February announced an
        extension of the Accelerating Access Initiative to enable employers and
        NGOs, working on the ground in developing countries, to purchase the
        necessary medicines at preferential prices.
 
     5) In addition to HIV/AIDS, GSK is making significant contributions to
        combat other health problems in the developing world, including
        malaria, tuberculosis, Lymphatic Filariasis, and childhood
        immunization.
 
     Lymphatic Filariasis (LF): The company is working to help eradicate
 Lymphatic Filariasis, one of the world's major tropical diseases that causes
 life-long disability and disfigurement, through grants for public-private
 partnerships and donations of albendazole.  GSK has committed to donating
 albendazole for 15-20 years until LF is eliminated, making this the largest
 drug donation programme in history.
 
     Vaccines:  In addition to donating vaccines to a number of countries for
 specific programmes, the company continues to research better vaccines against
 diseases that affect developing countries, including malaria, tuberculosis and
 HIV/AIDS.
 
     Action TB:  Glaxo Wellcome established the Action TB fund in 1993.  This
 international, co-ordinated research programme aims to find new targets for
 anti-TB therapies, and identify novel vaccine candidates and surrogate markers
 for use in clinical trials.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X25437144
 
 SOURCE  GlaxoSmithKline plc